Disclosed is a binding molecule comprising at least one pharmacologically active agent and at least one binding site that binds to TMEM30A, wherein the at least one binding site that binds to TMEM30A is fused (i) directly or (ii) via an intervening amino acid sequence to the N-terminus of an Fc moiety. Also disclosed is the use of such a binding molecule in the manufacture of a medicament for treatment of a neurological disorder.